What is Claim d is:

1. An acid addition salt of sertraline:



wherein said salt is selected from the group consisting of the p-toluenesulfonic acid salt, the fumaric acid salt, the benzenesulfonic acid salt, the benzoic acid salt, the L-tartaric acid salt and the (-)-camphor-10-sulfonic acid salt.

2. The salt according to claim 1 wherein the salt is the p-toluenesulfonic acid salt.

3. The salt according to claim 2 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 16.6 degrees ± 0.2 degrees as measured with copper radiation.

4. The salt according to claim 2 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (± 0.2)	d-value (Å) (± 0.2)
6.5	13.6
16.1	5.5
16.6	5.3
20.0	4.4
23.7	3.8
24.0	3.7
25.8	3.5
28.5	3.1

5. The salt according to claim 2 characterized in having an onset of melting transition at about 260 °C.

6. The salt according to claim 1 wherein the salt is the fumaric acid salt.

7. The salt according to claim 6 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 15.5 degrees ± 0.2 degrees as measured with copper radiation.

8. The salt according to claim 6 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (± 0.2)	d-value (Å) (± 0.2)
13.9	6.4
15.5	5.7
18.3	4.8
19.1	4.6
20.8	4.3
23.0	3.9
23.4	3.8
27.4	3.2

9. The salt according to claim 6 characterized in having an onset of melting transition at about 187 °C.

10. The salt according to claim 1 wherein the salt is the benzenesulfonic acid salt.

11. The salt according to claim 10 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 19.8 degrees ± 0.2 degrees as measured with copper radiation.

12. The salt according to claim 10 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in Å, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (± 0.2)	d-value (Å) (± 0.2)
7.5	11.9
15.1	5.9
22.4	4.0
22.9	3.9
23.4	3.8
24.4	3.6
24.8	3.6
27.9	3.2

13. The salt according to claim 10 characterized in having a solid-solid transition at about 185 °C and an onset of melting transition at about 230 °C.

14. The salt according to claim 1 wherein the salt is the benzoic acid salt.

15. The salt according to claim 14 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 16.1 degrees ± 0.2 degrees as measured with copper radiation.

16. The salt according to claim 14 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (± 0.2)	d-value (Å) (± 0.2)
15.0	5.9
16.1	5.5
18.0	4.9
19.3	4.8
19.3	4.6
23.6	4.4
25.0	3.6
25.2	3.5

17. The salt according to claim 14 characterized in having an onset of melting transition at about 154 °C.

18. The salt according to claim 1 wherein the salt is the L-tartaric acid salt.

19. The salt according to claim 18 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 15.0 degrees ± 0.2 degrees as measured with copper radiation.

20. The salt according to claim 18 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (± 0.2)	d-value (Å) (± 0.2)
13.7	5.9
15.0	5.9
16.7	5.3
18.4	4.8
20.5	4.3
22.1	4.0
22.9	3.9
24.5	3.6

21. The salt according to claim 22 characterized in having an onset of melting transition at about 184 °C.

22. The salt according to claim 1 wherein the salt is the (-)-camphor-10-sulfonic acid salt.

23. The salt according to claim 22 having an x-ray diffraction pattern characterized substantially by an x-ray diffraction pattern peak expressed in terms of an angle 2θ of 5.6 degrees ± 0.2 degrees as measured with copper radiation.

24. The salt according to claim 22 having an x-ray diffraction pattern characterized substantially by the following principal x-ray diffraction pattern peaks expressed in terms of an angle of 2θ degrees and d-spacings in E, within the margins of error indicated, as measured with copper radiation:

Angle 2θ (± 0.2)	d-value (Å) (± 0.2)
5.6	15.8
13.1	6.8
14.6	6.8
15.8	5.6
18.2	4.9
19.9	4.5
21.7	4.1
22.6	3.9

25. The salt according to claim 22 characterized in having an onset of melting transition at about 265 °C.

26. A pharmaceutical composition comprising a salt according to claim 1 and a pharmaceutically acceptable carrier or excipient.

27. A method of treating in a mammal a disease, disorder or condition selected from the group consisting of aggression disorders; anxiety disorders, panic attack, agoraphobia, panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder and acute stress disorder; cognitive disorders selected from the group consisting of amnestic disorders, amnestic disorders due to a general medical condition, substance-induced persisting amnestic disorder and amnestic disorders not otherwise specified, deliriums, deliriums due to a general medical condition, substance-induced delirium and delirium not otherwise specified, dementias, dementia of the Alzheimer's type, vascular dementia, dementia due to a general medical condition; AIDS-, Parkinson's-, head trauma-, and Huntington's-induced dementias; substance-induced persisting dementia, dementia due to multiple etiologies; depression disorders; emesis; epilepsy; food-related behavioral disorders, anorexia nervosa, bulimia; headache disorders, migraine; cluster and vascular headaches; learning disorders, attention deficit disorder, attention deficit/hyperactivity disorder; obesity; ocular disorders; platelet aggregation disorders; psychotic conditions, schizophrenia, paranoid-type schizophrenia, disorganized-type schizophrenia, catatonic-type schizophrenia, undifferentiated-type schizophrenia, residual-type schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorders due to a general medical condition; sleep disorders, primary sleep disorders, parasomnias, dyssomnias, sleep disorders related to another mood and anxiety disorders, sleep disorders due to a general medical condition; sexual behavior disorders; substance-abuse disorders, alcohol-related disorders; alcohol-use disorders selected from dependence and abuse disorders; alcohol-induced disorders selected

from intoxication, withdrawal, intoxication delirium, withdrawal delirium, persisting dementia, persisting amnestic, mood, anxiety, sexual dysfunction, and sleep disorders; amphetamine-related disorders; amphetamine-use disorders selected from dependence and abuse disorders; amphetamine-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, anxiety, sexual dysfunction and sleep disorders; caffeine-related disorders selected from as intoxication, induced-anxiety disorder, induced-sleep disorder; cannabis-related disorders, cannabis-use disorders selected from abuse and dependence disorders; cannabis-induced disorders selected from intoxication, intoxication delirium, psychotic disorder, and anxiety disorders; cocaine-related disorders; cocaine-use disorders selected from dependence and abuse disorders; cocaine-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, anxiety, sexual dysfunction, sleep disorder; hallucinogen-related disorders, hallucinogen-use disorders selected from dependence and abuse disorders; hallucinogen-induced disorders selected from intoxication, persisting perception, intoxication delirium, psychotic, mood, and anxiety disorder; inhalant-related disorders, inhalant-use disorders selected from dependence and abuse disorders; inhalant-induced disorders selected from intoxication, intoxication delirium, persisting dementia, psychotic, mood, and anxiety disorder; nicotine-related disorders selected from dependence and withdrawal; opioid-related disorders, opioid-use disorders selected form dependence and abuse disorders; opioid-induced disorders selected from intoxication, withdrawal, intoxication delirium, psychotic, mood, sexual dysfunction, and sleep disorder; phencyclidine-related disorders, phencyclidine-use disorders selected from dependence and abuse disorder; phencyclidine-induced disorders selected from intoxication, intoxication delirium, psychotic, mood, and anxiety disorder; sedative-, hypnotic- or anxiolytic-related disorders, sedative-use disorders selected from dependence and abuse disorders; sedative-induced disorders selected from intoxication, withdrawal, intoxication delirium, withdrawal delirium, persisting dementia, persisting amnestic, psychotic, mood, anxiety, sexual dysfunction, and sleep disorders; polysubstance-related disorder, vision disorders, and glaucoma; comprising administering to a subject in need thereof a therapeutically effective amount of a salt according to claim 1.